Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development
- PMID: 26318164
- PMCID: PMC4577199
- DOI: 10.1073/pnas.1513935112
Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development
Conflict of interest statement
Conflict of interest statement: The authors are employees of Regeneron Pharmaceuticals, Inc.
Comment on
-
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. Epub 2015 Jun 29. Proc Natl Acad Sci U S A. 2015. PMID: 26124093 Free PMC article.
-
No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses.Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5115. doi: 10.1073/pnas.1513441112. Epub 2015 Aug 28. Proc Natl Acad Sci U S A. 2015. PMID: 26318165 Free PMC article. No abstract available.
References
-
- Bradbury A, Plückthun A. Reproducibility: Standardize antibodies used in research. Nature. 2015;518(7537):27–29. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources